The effectiveness of the combination of INCMGA00012 (anti-PD-1 antibody), INCAGN02385 (anti-LAG-3 antibody), and INCAGN02390 (anti-TIM-3 antibody) is under evaluation in a phase I/II clinical study in melanoma patients (NCT04370704). The gene discussed is LAG3; the disease is melanoma.